Skip directly to site content
Are You Still There?
Due to inactivity, you will be signed out in two minutes unless you click 'Continue'.

Are you still there?

Due to inactivity, you will be signed out in two minutes unless
you click 'Continue'.

Panel:   Plazomicin (PLZ)
AR Bank # 0844 Proteus mirabilis
Study ID: PLZ-14

Biosample Accession #: SAMN11953894

   
Location: Portugal
MLST: Unknown

MICs obtained by broth microdilution. Modal MIC is reported.

MIC results for each antimicrobial agent for an isolate may commonly be ± 1 log2 (doubling dilution) different than what is posted on the FDA & CDC AR Bank website because this is the normal technical variability of antimicrobial susceptibility testing (see J. H. Jorgensen. 1993. J Clin Microbiol. Vol 31[11]: 2841-2844).

Panel:  Plazomicin (PLZ)


MIC (μg/ml) Results and Interpretation
Drug MIC (μg/ml) INT
Amikacin 2S
Ampicillin >32R
Ampicillin/sulbactam 18S
Aztreonam <=2S
Aztreonam/avibactam 1 2<=0.03S
Cefazolin >8R
Cefepime <=0.5S
Cefotaxime <=0.5S
Cefotaxime/clavulanic acid 1 5<=0.25---
Cefoxitin 8S
Ceftazidime <=1.0S
Ceftazidime/avibactam 1<=0.5S
Ceftazidime/clavulanic acid 1 5<=0.5---
Ceftolozane/tazobactam 1<=0.5S
Ceftriaxone <=1.0S
Ciprofloxacin 4R
Colistin 4>8R
Doripenem 0.25S
Ertapenem <=0.12S
Gentamicin >16R
Imipenem 2I
Imipenem+chelators 32---
Levofloxacin 2R
Meropenem <=0.12S
Piperacillin/tazobactam 1<=4S
Plazomicin 2S
Tetracycline >32R
Tigecycline 2 4>4R
Tobramycin 16R
Trimethoprim/sulfamethoxazole 1<=0.5S
S – I –R Interpretation (INT) derived from CLSI 2025 M100 S35
1 Reflects MIC of first component
2 Based on FDA break points
3 Screen for metallo-beta-lactamase production [Rasheed et al. Emerging Infectious Diseases. 2013. 19(6):870-878]
4 Clinical and PK/PD data demonstrate colistin has limited clinical efficacy, even if an intermediate result is obtained. Alternative agents are strongly preferred. Colistin should be used in combination with one or more active antimicrobial agents. Consultation with an infectious disease specialist is recommended.
4 The interpretation of resistant is due to intrinsic resistance for this species-drug combination rather than the MIC. Refer to CLSI M100 for more information about intrinsic resistance
5 Screen test for Extended-Spectrum-β-lactamase (ESBL) production (CLSI M100). Per CLSI, use of the ESBL test is limited to isolates of Klebsiella pneumoniae, K. oxytoca, Escherichia coli, and Proteus mirabilis. It should be noted that the presence of other β-lactamases (carbapenemases and/or AmpC) or porin alterations can mask the ESBL production and confound the interpretation of the ESBL screen test.
Device manufacturers and users of FDA cleared devices shall consult the FDA’s Antibacterial Susceptibility Test Interpretive Criteria       website for breakpoints recognized or recommended by FDA, and for information regarding FDA exceptions or additions to the applicable, recognized consensus standard.
Molecular Mechanisms of Resistance
CategoryGene
Aminoglycoside aac(3)-IIe, aph(3')-Ia, aph(6)-Id, strA
Sulfonamides sul2
Tetracyclines tet(B), tet(J)
 
Disclaimer:

Antimicrobial Resistance (AR) gene prediction was performed using a combined and deduplicated AR database (ResGANNCBI) from ARG-ANNOT, ResFinder and NCBI AMRFinder accessed on 2022-09-15. AR drug classes are assigned according to these databases. This analysis does not include mutations that may result in antimicrobial resistance, or resistance determinants added to newer versions of databases used, or other antimicrobial resistance gene databases. Additional AR genes other than those listed, may be present. For resistance determinant detection, 99-100% sequence identity and 100% sequence coverage from GAMMA and SRST2 was used. GAMMA uses amino acid sequence to assign gene alleles from assemblies; SRST2 uses nucleotide sequence to assign gene alleles from sequencing reads. Biosample accession numbers have been provided so that users can analyze the data on their own, if so desired.

*MLST Type (and scheme), as determined by Torsten Seemann's MLST program. For Enterobacterales the Pasteur MLST schemes are used except for E. coli for which both the Pasteur and Achtman schemes are reported. Similarly, for Acinetobacter baumannii complex, both Pasteur and Oxford MLST schemes are used and reported. SUB=novel MLST identified and "submitted". Dash (-) indicates no pubMLST scheme is available for that species.

Propagation
MEDIUM
Medium: Trypticase Soy Agar with 5% Sheep Blood (BAP)

GROWTH CONDITIONS
Temperature: 35°C
Atmosphere: Aerobic

PROPAGATION PROCEDURE

Remove the sample vial to a container with dry ice or a freezer block. Keep vial on ice or block. (Do not let vial content thaw)

Open vial aseptically to avoid contamination

Using a sterile loop, remove a small amount of frozen isolate from the top of the vial

Aseptically transfer the loop to BAP

Use streak plate method to isolate single colonies

Incubate inverted plate at 35°C ± 2°C for 18-24 hrs.
Storage Temperature & Biosafety
STORAGE TEMPERATURE: -70°C

BIOSAFETY LEVEL: 2

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the current publication of 'BioSafety in Microbiological and Biomedical Laboratories' from the U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, and National Institutes of Health.



Disclaimer:

This product is sent with the condition that you are responsible for its safe storage, handling, and use. All materials are the property of the Centers for Disease Control and Prevention (CDC) and have been made available on behalf of the Food and Drug Administration (FDA). This material is not for use in human subjects and may not be redistributed. While CDC uses reasonable efforts to include accurate and up-to-date information on this product sheet, CDC makes no warranties or representations as to its accuracy. CDC is not liable for damages arising from the misidentification or misrepresentation of cultures. Please refer to the Standard Letter Agreement (SLA) for further details regarding the use of this product.
Isolate History
Date Action Performed
03/20/25INT was updated with a new value for Aztreonam/avibactam: from '---' to 'S'
03/20/25MIC was updated with a new value for Aztreonam/avibactam: from '---' to '<=0.03'
03/20/25Drug was added: 'Aztreonam/avibactam'
08/22/23MLST was updated: from '---' to 'Unknown'
08/22/23Gene was added to 'tet(J)'
08/22/23Gene was added to 'aph(3')-Ia'
08/22/23Gene was added to 'aac(3)-IIe'
08/22/23Gene was removed from 'from '---' to ' aac(3)-IIa''
05/24/23Location was changed: from '---' to 'Portugal'
10/22/18New Isolate added to panel
Top of Page
TOP